Clinical trials: Ritonavir
Proteinuria, HIV
MARCH Renal Substudy
Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV. Antiretroviral therapy associated renal dysfunction has been predominantly described in terms of reduced glomerular filtration (eGFR).
- Trial name
- MARCHrenal (NCT01637259)
- Testing
- arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors, Arm 2 boosted protease inhibitors and maraviroc, Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
- Where
- 15 sites in Argentina, Australia and 6 more
- Volunteers
- 76 people
- Sponsor
- Kirby Institute
HIV Infections
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
- Trial name
- NCT00004582
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- United States
- Sponsor
- ViRx
Chronic Hepatitis c Genotype 1
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
- Trial name
- NCT04246723
- Testing
- Narlaprevir, Ritonavir, Sofosbuvir
- Where
- 5 sites in Russia
- Volunteers
- 85 people
- Sponsor
- R-Pharm
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02493855
- Testing
- Ombitasvir/ABT-450/Ritonavir, Dasabuvir, Ribavirin (RBV)
- Volunteers
- 46 people
- Sponsor
- AbbVie
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
HIV-infected Children
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
To compare the safety and efficacy of low-dose versus standard dose lopinavir/ritonavir containing HAART regimen in virological suppress, HIV RNA viral load < 50 copies/ml at 48 week
- Trial name
- NCT01307124
- Testing
- kaletra
- Where
- 10 sites in Thailand
- Volunteers
- 199 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Infection, Human Immunodeficiency Virus I
Fosamprenavir Versus Other Protease Inhibitors
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir.
- Trial name
- NCT00094523
- Testing
- Fosamprenavir
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- ViiV Healthcare
HIV Infections
Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
Kaletra (a combination drug with lopinavir and ritonavir) is one of a few effective medications that are approved and available for young children who are HIV+.
- Trial name
- NCT00762320
- Testing
- Low dose Kaletra tablets
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Phoenix Children's Hospital
Acquired Immune Deficiency Syndrome Virus
Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and…
- Trial name
- NCT02337322
- Testing
- Dolutegravir, Darunavir/r
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Juan A. Arnaiz
Human Immunodeficiency Virus (HIV)
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either…
- Trial name
- NCT00335322
- Testing
- Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz), Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV), Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
- Volunteers
- 329 people
- Sponsor
- Kirby Institute
HIV Infections
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy.
- Trial name
- NCT00002451
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19 Pneumonia
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.
- Trial name
- NCT05656443
- Testing
- GST-HG171/Ritonavir
- Where
- China
- Volunteers
- 1,246 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
HIV Infections
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including Lopinavir/ritonavir (LPV/RTV), as assessed by an increased…
- Trial name
- NCT00312754
- Testing
- Atazanavir
- Where
- 6 sites in France
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in…
- Trial name
- NCT00885495
- Testing
- darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
HIV Infection
Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
Pilot, randomized, parallel, open-label, controlled, clinical study evaluating virological response in plasma and extra-plasmatic compartments, together with the degree and kinetics of immune reconstitution in treatment-naïve…
- Trial name
- NCT00386659
- Testing
- tenofovir + abacavir + lopinavir/ritonavir, tenofovir + abacavir + efavirenz
- Where
- 4 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Clinic of Barcelona
Human Immunodeficiency Virus 1
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination…
- Trial name
- MONARCH (NCT01391013)
- Testing
- Darunavir(DRV), Ritonavir, 2 nucleoside reverse transcriptase inhibitors (NRTIs)
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV
A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study
The purpose of the study is to investigate the possible benefits of giving the anti-HIV drug maraviroc to people who are taking darunavir/ritonavir alone for their HIV treatment.
- Trial name
- CINAMMON (NCT01680536)
- Testing
- maraviroc
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- St Stephens Aids Trust
COVID-19
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to…
- Trial name
- NCT04434248
- Testing
- Favipiravir, Standard of Care
- Where
- 22 sites in Russia
- Volunteers
- 330 people
- Sponsor
- Chromis LLC
COVID-19 Drug Treatment
A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
The purpose of this study is to collect information on the: general information of a group of people such as their age, sex, and other facts. clinical information of the patients such as any other illness before having COVID 19.
- Trial name
- NCT05997485
- Testing
- Nirmatrelvir/Ritonavir
- Sponsor
- Pfizer
HIV Infections
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks).
- Trial name
- DAYANA (NCT00573001)
- Testing
- Tenofovir/Emtricitabine (Truvada) and Nevirapine, Tenofovir/Emtricitabine/Efavirenz (Atripla), Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 120 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis